Core Viewpoint - Aldeyra Therapeutics, Inc. is focused on developing innovative therapies for immune-mediated diseases and will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] Company Participation - Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will engage in a virtual fireside chat at the conference [1] - The discussion will be moderated by Andreas Argyrides, Managing Director, Senior Biotech [1]

Core Insights - Precision BioSciences announced that new preclinical study data for PBGENE-DMD will be presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, highlighting its potential safety and long-term efficacy [1] Company Overview - Precision BioSciences, Inc. is a clinical-stage gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs [1] - The company has received Investigational New Drug clearance from the U.S. FDA for PBGENE-DMD, allowing the initiation of clinical trial site activation [1] Product Details - PBGENE-DMD is a first-in-class gene editing therapy designed to provide durable functional muscle improvement for Duchenne Muscular Dystrophy (DMD) patients with mutations between exons 45 and 55, affecting up to 60% of boys with DMD [1] - The therapy employs a gene excision approach, differentiating it from existing treatments like microdystrophin and exon skipping [1] - Preclinical studies demonstrated significant and durable functional improvements in a humanized DMD mouse model, restoring production of a near full-length functional dystrophin protein across multiple muscle types [1] Clinical Development - The upcoming presentation at the MDA conference will focus on the abstract titled "PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse model" [1] - The presentation is scheduled for March 9, 2026, and will be a poster presentation [1]

Sobi Capital Markets Day 2026 18 February 2026 Forward-looking statements In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Swedish Orphan Biovitrum AB (publ), By their nature, forward-looking statements and forecasts invol ...

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast ...

Core Insights - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune diseases [1] - The company will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, with a webcast available for 90 days post-event [1] Company Overview - Q32 Bio targets potent regulators of the adaptive immune system to develop innovative therapies for alopecia areata and other autoimmune and inflammatory diseases [1] - Approximately 700,000 individuals in the U.S. are affected by alopecia areata, which significantly impacts their lives and has limited treatment options [1] Product Development - Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R antibody, currently in a Phase 2 program for treating alopecia areata [1] - The IL-7 and TSLP pathways are implicated in various T cell-mediated autoimmune diseases, highlighting the potential of Q32 Bio's therapeutic approach [1]

Core Insights - Merck and Mayo Clinic have announced a strategic collaboration to leverage AI and advanced analytics for drug discovery and precision medicine, integrating Mayo Clinic's clinical insights and genomic data with Merck's AI capabilities [1] Collaboration Details - The partnership will utilize Mayo Clinic's Platform architecture and multimodal clinical data to enhance disease understanding and improve target identification for drug development [1] - This collaboration marks Mayo Clinic's first strategic partnership of this scale with a global biopharmaceutical company [1] Focus Areas - The initial focus will be on three therapeutic areas: - Neurology: Multiple sclerosis - Dermatology: Atopic dermatitis - Gastroenterology: Inflammatory bowel disease (IBD) [1] Technology Integration - Merck will access Mayo Clinic's de-identified clinical data, including laboratory results, medical imaging, clinical notes, and molecular data, to validate AI models and translate research insights into actionable strategies [1] - The collaboration aims to speed up the development of innovative therapies by combining clinical expertise with advanced AI tools [1] Company Background - Merck, known as MSD outside the U.S. and Canada, has a long history of developing important medicines and vaccines, aspiring to be a premier research-intensive biopharmaceutical company [1] - Mayo Clinic is a nonprofit organization focused on innovation in clinical practice, education, and research, committed to providing compassionate care [1]

Core Viewpoint - CervoMed Inc. has announced that its investigational drug neflamapimod has been included in the EXPERTS-ALS platform for rapid testing in amyotrophic lateral sclerosis (ALS), with the first patient expected to be dosed by the end of 2026 [1][4] Group 1: Neflamapimod and Its Mechanism - Neflamapimod is an oral small molecule drug candidate that targets critical disease processes underlying neurodegenerative disorders by selectively inhibiting p38 MAP kinase, a key driver of neuroinflammation [6][11] - The drug has shown positive clinical activity in dementia with Lewy bodies, demonstrating a potent effect on blood biomarkers of neurodegeneration [3][8] - Neflamapimod is currently in clinical development for multiple indications, including dementia with Lewy bodies, recovery after ischemic stroke, and primary progressive aphasia [7][11] Group 2: EXPERTS-ALS Platform - EXPERTS-ALS is a UK-based platform designed to rapidly evaluate potential therapies for ALS through a randomized, multicenter trial that measures neurofilament light chain (NfL) levels, which correlate with disease progression [2][9] - The initial evaluation of neflamapimod will involve approximately 35 ALS participants over 18-24 weeks, with the potential to expand to a total of 80 patients [2] - The platform is funded by the UK National Institute for Health and Care Research and supported by various motor neuron disease charities [2][9] Group 3: Clinical Trial Insights - Previous clinical trials of neflamapimod have involved over 800 participants, showing it to be generally well tolerated and effective in improving dementia severity and functional mobility in patients with dementia with Lewy bodies [8] - The Phase 2a AscenD-LB trial and Phase 2b RewinD-LB trial provided evidence of neflamapimod's potential clinical benefits, particularly in patients without Alzheimer's disease co-pathology [8] Group 4: ALS Overview - Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting approximately 168,000 people worldwide, with no approved therapies to stop or reverse its progression [5]

Core Viewpoint - Vertex Pharmaceuticals has demonstrated its ability to develop successful drugs and generate earnings growth, positioning itself as a strong investment opportunity regardless of market conditions [1][2]. Company Overview - Vertex is the global leader in cystic fibrosis (CF) treatment and has expanded into gene editing for blood disorders and pain management, which supports sustained earnings growth [2][5]. - The company produces CFTR modulators that address approximately 90% of genetic mutations associated with CF, significantly improving the quality of life for patients [5][6]. Financial Performance - Vertex expects its non-CF products, including the gene editing treatment Casgevy and pain drug Journavx, to contribute over $500 million to revenue this year [7]. - The total revenue guidance for Vertex for the year is projected to reach as high as $13.1 billion [7]. Investment Strategy - Vertex is characterized as a "compounder," indicating its potential for long-term value appreciation, making it a suitable addition to a diversified investment portfolio [4]. - The company's strong intellectual property portfolio is expected to support its leadership in CF treatment for the coming decade, providing stability and growth for investors [6].

Core Insights - BioArctic reported a transformative year with record financial results, including an operating profit exceeding SEK 1.2 billion and a doubling of cash position [1][2] - The company proposed a dividend of SEK 2.00 per share for the financial year 2025, reflecting its strong financial position [2] Financial Summary - Cash and cash equivalents and short-term investments at the end of the period amounted to SEK 2,190.4 million, up from SEK 778.9 million [1] - Cash flow from operating activities was SEK 313.3 million, compared to a negative SEK 27.4 million in the previous year [1] - Earnings per share before and after dilution were SEK -0.10, improving from SEK -0.36 [1] - Profit for the period was SEK -8.8 million, an improvement from SEK -31.5 million [1] - Operating profit was SEK 33.2 million, compared to SEK -53.5 million in the previous year [1] - Net revenues reached SEK 184.0 million, up from SEK 101.2 million, with SEK 127.0 million in royalties from Leqembi [1] Product Development and Regulatory Updates - Leqembi was approved in over 50 markets, with sales growing each quarter; royalty revenues increased by 31% year-on-year despite currency impacts [1] - The subcutaneous version of Leqembi, Leqembi Iqlik, was launched for maintenance treatment in the US, allowing for home administration [1] - Regulatory reviews for Leqembi Iqlik are ongoing in the US, China, and Japan, with priority reviews granted by the FDA and EMA [1] - The company is working to broaden the availability of Leqembi in Nordic countries and is addressing regulatory challenges in Europe [1] Research and Development Initiatives - BioArctic has strengthened its project portfolio with new initiatives in Huntington's disease and Parkinson's disease, alongside advancing existing projects [1] - Candidate drugs for two projects are being prepared for clinical studies, including one in ALS and another in Parkinson-related disorders [1] - The company is investing in its BrainTransporter technology to enhance the delivery of treatments across the blood-brain barrier [1] - Strong interest in BioArctic's technology and projects has been noted, with opportunities for new strategic partnerships anticipated [1]

Core Insights - Zealand Pharma announced positive Phase 1a topline results for ZP9830, a Kv1.3 channel blocker, indicating favorable safety and tolerability in healthy male participants [2][4] Group 1: Phase 1a Trial Results - The Phase 1a trial was a single ascending dose (SAD) study designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ZP9830 [2][5] - ZP9830 was well tolerated with no dose-limiting safety findings or serious adverse events reported [3][8] - Pharmacokinetic parameters showed a dose-proportional increase, and the intravenous cohort demonstrated high bioavailability of the subcutaneous formulation [3][8] Group 2: ZP9830 Overview - ZP9830 is a selective Kv1.3 channel blocker with potential applications in treating various immune-mediated inflammatory diseases [6][8] - The Kv1.3 channel is selectively upregulated on effector memory T cells, which are involved in autoimmunity and chronic inflammation [6][7] Group 3: Company Background - Zealand Pharma focuses on advancing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise [8][9] - The company has successfully developed multiple drug candidates, with two products already on the market and three in late-stage development [9]